Low-Dose Esketamine in Emergency C-Sections: RCT Evidence from China

Randomized Trial Finds Low-Dose Esketamine Safe and Effective for Emergency Cesarean Pain and Sedation

A randomized controlled trial (RCT) published on October 12, 2026, in the Chinese Clinical Trial Registry (ChiCTR2600121948) provides direct evidence that low-dose intravenous esketamine (0.15 mg/kg) is both safe and effective for improving pain control and sedation during emergency conversion from labor epidural analgesia to Category I cesarean section. The study, conducted in China, enrolled 55 parturients (31 esketamine, 24 saline control) requiring urgent C-section after failed epidural analgesia. The primary outcome—change in maternal systolic blood pressure over 20 minutes—showed no meaningful difference between groups, indicating cardiovascular stability. Secondary outcomes revealed reduced intraoperative pain and improved sedation in the esketamine group, with no adverse signal in maternal heart rate, oxygenation, or early neonatal Apgar scores.

Mechanism, Context, and Clinical Rationale

Esketamine, the S-enantiomer of ketamine, is a dissociative anesthetic with rapid onset and a favorable safety profile at low doses. Unlike classic psychedelics, esketamine at sub-anesthetic doses acts primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, modulating pain pathways and providing mild sedation without deep anesthesia. In the context of emergency obstetric surgery, time constraints often preclude adequate epidural top-up, creating a critical need for fast-acting adjuncts that do not compromise maternal or fetal safety. This study’s protocol—administering esketamine one minute before incision alongside alkalinized lidocaine—reflects a pragmatic approach to bridging analgesia during high-stakes, time-pressured procedures. Notably, the trial did not observe increased muscle relaxation, suggesting that esketamine’s benefits are primarily analgesic and sedative rather than neuromuscular.

Policy, Regulatory, and Research Implications

The absence of negative effects on maternal hemodynamics or early neonatal outcomes in this RCT is a significant finding for clinicians and regulators considering the broader adoption of ketamine analogs in acute care. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA) have historically been cautious about off-label anesthetic use in obstetrics due to potential risks to both mother and infant. This trial’s results, registered under ChiCTR2600121948, provide first-party evidence supporting the safety profile of low-dose esketamine in a peripartum emergency setting. For hospital protocols and anesthesia guidelines, this could justify the inclusion of esketamine as a bridging agent in specific obstetric emergencies—pending replication and further safety monitoring. Importantly, the study’s detailed hemodynamic monitoring and neonatal Apgar scoring address key regulatory concerns about short-term safety, though longer-term neurodevelopmental outcomes remain unstudied.

• Clinical Practice: The findings may prompt anesthesiology societies to revisit recommendations on adjunctive agents during urgent C-sections, especially where rapid conversion is required.
• Research: The trial highlights an evidence gap in peripartum pharmacology, suggesting a need for larger, multi-center studies and long-term neonatal follow-up.
• Regulatory: The clear reporting of both maternal and neonatal endpoints provides a model for future trials seeking regulatory acceptance of novel anesthetic protocols.

Risks, Limitations, and Unknowns

Despite promising results, several risks and unknowns remain. The sample size (n=55) limits the power to detect rare adverse events, and the study’s single-center design may not generalize to diverse populations or healthcare systems. While no immediate negative effects on maternal blood pressure, heart rate, or oxygenation were observed, and median Apgar scores were high in both groups, the trial did not assess longer-term neurodevelopmental or behavioral outcomes in neonates. Esketamine’s dissociative and psychotomimetic effects, though minimal at this dose, warrant caution in patients with psychiatric vulnerabilities. Additionally, the retrospective trial registration (ChiCTR2600121948) could raise questions about protocol adherence and reporting transparency in some regulatory environments. A subtle but important consideration is the potential for esketamine to mask pain that may signal surgical complications, underscoring the need for vigilant intraoperative monitoring.

Looking Forward: Broader Implications and Next Steps

This RCT adds to a growing body of evidence supporting the judicious use of sub-anesthetic ketamine analogs in acute and peripartum care. For clinicians, the results offer a practical, evidence-based option for managing pain and sedation during emergency C-sections when standard epidural analgesia fails. For policymakers and hospital administrators, the trial’s safety data may inform updates to obstetric anesthesia protocols, especially in resource-limited or high-volume settings. Future research should prioritize larger, prospective studies with diverse populations and long-term neonatal follow-up to fully characterize the risk-benefit profile. A non-obvious implication is that successful integration of esketamine protocols in obstetric emergencies could pave the way for its use in other acute care scenarios where rapid, safe analgesia is needed, potentially shifting the risk calculus for both regulatory approval and clinical adoption.

How we research: This article was written and reviewed by Dr. Alex Lin, MD, PhD (Anesthesiology, Peripartum Pharmacology), on 2026-10-13. Primary data were sourced directly from the Chinese Clinical Trial Registry and the published trial report.